Description

AQUAZIDE 12.5 MG

Indications

AQUAZIDE 12.5 MG, containing the active ingredient hydrochlorothiazide, is primarily indicated for the management of hypertension and the treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disorders. It is often utilized as part of a comprehensive treatment plan that may include other antihypertensive agents or diuretics to achieve optimal blood pressure control and fluid balance.

Mechanism of Action

The therapeutic effects of AQUAZIDE 12.5 MG are attributed to its action as a thiazide diuretic. Hydrochlorothiazide works by inhibiting the sodium-chloride symporter in the distal convoluted tubule of the nephron, leading to increased excretion of sodium and chloride ions. This diuretic effect results in increased urine output and a reduction in blood volume, which subsequently lowers blood pressure. Additionally, the decrease in extracellular fluid volume alleviates edema, making AQUAZIDE effective in managing fluid retention.

Pharmacological Properties

AQUAZIDE 12.5 MG exhibits several pharmacological properties that contribute to its efficacy. Hydrochlorothiazide is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically reached within 1-2 hours post-administration. The drug has a half-life of approximately 6-15 hours, allowing for once-daily dosing in most cases. Hydrochlorothiazide is primarily excreted unchanged via the kidneys, and its diuretic effects generally begin within 2 hours of administration, lasting for approximately 6-12 hours. The drug also has a mild vasodilatory effect, which may further assist in blood pressure reduction.

Contraindications

AQUAZIDE 12.5 MG is contraindicated in patients with known hypersensitivity to hydrochlorothiazide or any component of the formulation. It should not be used in individuals with anuria, as it is ineffective in patients with severely impaired renal function. Additionally, caution is advised in patients with a history of gout, as hydrochlorothiazide may elevate uric acid levels and precipitate gout attacks. Pregnant and lactating women should also consult their healthcare provider before using this medication, as its safety during pregnancy and lactation has not been fully established.

Side Effects

Common side effects associated with AQUAZIDE 12.5 MG include electrolyte imbalances, such as hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypercalcemia (high calcium levels). Other potential side effects may include dizziness, headache, gastrointestinal disturbances (nausea, vomiting, diarrhea), and skin rashes. In rare cases, more serious adverse effects such as pancreatitis, hepatic dysfunction, or severe allergic reactions may occur. Patients should be monitored for these side effects, especially during the initiation of therapy or when dosage adjustments are made.

Dosage and Administration

The recommended starting dose of AQUAZIDE 12.5 MG for the treatment of hypertension is typically 12.5 mg once daily. Depending on the patient’s response and clinical condition, the dosage may be adjusted, with a maximum daily dose of 50 mg. For the management of edema, the initial dose may also start at 12.5 mg, with titration based on clinical response. It is advised to take AQUAZIDE in the morning to minimize nocturia. The tablets should be swallowed whole with water and can be taken with or without food. Regular monitoring of blood pressure, renal function, and electrolyte levels is recommended during treatment.

Interactions

AQUAZIDE 12.5 MG may interact with various medications, which could enhance the risk of side effects or reduce therapeutic efficacy. Notably, the concurrent use of other antihypertensive agents may lead to additive blood pressure-lowering effects, requiring careful monitoring and potential dosage adjustments. Non-steroidal anti-inflammatory drugs (NSAIDs) may decrease the diuretic effect of hydrochlorothiazide. Additionally, the use of corticosteroids may exacerbate electrolyte imbalances. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with AQUAZIDE 12.5 MG, a thorough medical history and physical examination should be conducted. Special caution is warranted in patients with a history of renal impairment, diabetes mellitus, or electrolyte disturbances. Regular monitoring of renal function and serum electrolytes is essential, particularly in elderly patients or those with comorbid conditions. Patients should be advised to maintain adequate hydration, especially during hot weather or strenuous exercise, to prevent dehydration and associated complications. Discontinuation of the medication may be necessary if significant adverse effects or electrolyte imbalances occur.

Clinical Studies

Clinical studies have demonstrated the efficacy of AQUAZIDE 12.5 MG in reducing blood pressure in hypertensive patients and managing edema in various clinical settings. A randomized controlled trial published in the Journal of Hypertension showed that hydrochlorothiazide effectively lowered systolic and diastolic blood pressure compared to placebo, with a favorable safety profile. Another study indicated that the use of AQUAZIDE in combination with other antihypertensive agents resulted in improved blood pressure control and reduced incidence of cardiovascular events. These studies support the role of AQUAZIDE as a valuable therapeutic option in the management of hypertension and fluid retention.

Conclusion

AQUAZIDE 12.5 MG is a well-established thiazide diuretic that plays a crucial role in the management of hypertension and edema. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable component of treatment regimens for patients with these conditions. However, careful consideration of contraindications, potential side effects, and drug interactions is essential to ensure safe and effective use. Patients should be educated about the importance of adherence to prescribed therapy and regular monitoring to optimize treatment outcomes.